These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 27910071)
21. Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss. Mori N; Kyo S; Sakaguchi J; Mizumoto Y; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M Cancer Sci; 2007 Dec; 98(12):1881-8. PubMed ID: 17924977 [TBL] [Abstract][Full Text] [Related]
22. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148 [TBL] [Abstract][Full Text] [Related]
23. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Oda K; Stokoe D; Taketani Y; McCormick F Cancer Res; 2005 Dec; 65(23):10669-73. PubMed ID: 16322209 [TBL] [Abstract][Full Text] [Related]
24. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Hayes MP; Wang H; Espinal-Witter R; Douglas W; Solomon GJ; Baker SJ; Ellenson LH Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5932-5. PubMed ID: 17062663 [TBL] [Abstract][Full Text] [Related]
25. Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Catasus L; D'Angelo E; Pons C; Espinosa I; Prat J Mod Pathol; 2010 May; 23(5):694-702. PubMed ID: 20173732 [TBL] [Abstract][Full Text] [Related]
26. Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway. Martinez JD; Mo Q; Xu Y; Qin L; Li Y; Xu J Int J Biol Sci; 2022; 18(1):229-241. PubMed ID: 34975329 [TBL] [Abstract][Full Text] [Related]
27. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572 [TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis. Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935 [TBL] [Abstract][Full Text] [Related]
29. Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Memarzadeh S; Zong Y; Janzen DM; Goldstein AS; Cheng D; Kurita T; Schafenacker AM; Huang J; Witte ON Proc Natl Acad Sci U S A; 2010 Oct; 107(40):17298-303. PubMed ID: 20855612 [TBL] [Abstract][Full Text] [Related]
30. Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor α. Joshi A; Wang H; Jiang G; Douglas W; Chan JS; Korach KS; Ellenson LH Am J Pathol; 2012 Jun; 180(6):2536-47. PubMed ID: 22503752 [TBL] [Abstract][Full Text] [Related]
31. DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice. Wang H; Douglas W; Lia M; Edelmann W; Kucherlapati R; Podsypanina K; Parsons R; Ellenson LH Am J Pathol; 2002 Apr; 160(4):1481-6. PubMed ID: 11943731 [TBL] [Abstract][Full Text] [Related]
32. PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine. Davies EJ; Marsh Durban V; Meniel V; Williams GT; Clarke AR J Pathol; 2014 May; 233(1):27-38. PubMed ID: 24293351 [TBL] [Abstract][Full Text] [Related]
33. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Hafsi S; Pezzino FM; Candido S; Ligresti G; Spandidos DA; Soua Z; McCubrey JA; Travali S; Libra M Int J Oncol; 2012 Mar; 40(3):639-44. PubMed ID: 22200790 [TBL] [Abstract][Full Text] [Related]
34. PTEN Mouse Models of Cancer Initiation and Progression. Lee YR; Pandolfi PP Cold Spring Harb Perspect Med; 2020 Feb; 10(2):. PubMed ID: 31570383 [TBL] [Abstract][Full Text] [Related]
35. [The relationship between PTEN expression and PI3K/AKT signal pathway in colon carcinoma]. Qi JK; Huang XL; Meng ZM; Gan HT; Fu DG Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul; 40(4):644-6, 654. PubMed ID: 19764563 [TBL] [Abstract][Full Text] [Related]
36. Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies. Xi Y; Chen Y J Cell Biochem; 2015 Sep; 116(9):1837-47. PubMed ID: 25773992 [TBL] [Abstract][Full Text] [Related]
37. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer. Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293 [TBL] [Abstract][Full Text] [Related]
38. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Fang J; Ding M; Yang L; Liu LZ; Jiang BH Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033 [TBL] [Abstract][Full Text] [Related]